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Abstract  23 
Background 24 
The ability to synthesize chiral building block molecules with high optical purity is of 25 
considerable importance to the fine chemical and pharmaceutical industries. Production 26 
of one such compound, 3-hydroxyvalerate (3HV), has previously been studied with 27 
respect to the in vivo or in vitro enzymatic depolymerization of biologically-derived co-28 
polymers of poly(3-hydroxybutyrate-co-3-hydroxyvalerate).  However, production of this 29 
biopolymeric precursor typically necessitates the supplementation of a secondary carbon 30 
source (e.g., propionate) into the culture medium. In addition, previous approaches for 31 
producing 3HV have not focused on its enantiopure synthesis, and thus suffer from 32 
increased costs for product purification. 33 
Results 34 
Here, we report the selective biosynthesis of each 3HV stereoisomer from a single, 35 
renewable carbon source using synthetic metabolic pathways in recombinant strains of 36 
Escherichia coli. The product chirality was controlled by utilizing two reductases of 37 
opposing stereoselectivity. Improvement of the biosynthetic pathway activity and host 38 
background was carried out to elevate both the 3HV titers and 3HV/3HB ratios. Overall, 39 
shake-flask titers as high as 0.31 g/L and 0.50 g/L of (S)-3HV and (R)-3HV, respectively, 40 
were achieved in glucose-fed cultures, whereas glycerol-fed cultures yielded up to 0.19 41 
g/L and 0.96 g/L of (S)-3HV and (R)-3HV, respectively.  42 
Conclusions 43 
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Our work represents the first report of direct microbial production of enantiomerically 44 
pure 3HV from a single carbon source. Continued engineering of host strains and 45 
pathway enzymes will ultimately lead to more economical production of chiral 3HV.  46 
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Background 47 
The efficient production of enantiomerically pure chemicals from renewable 48 
resources has gained considerable attention especially in the fine 49 
chemical/pharmaceutical industry. Stereo-selective chemical processes generally employ 50 
expensive chiral catalysts, require harsh physical conditions and solvents, and suffer from 51 
extensive byproduct formation. In contrast, enzyme-catalyzed reactions are highly stereo-52 
selective and can be performed in aqueous solutions under mild conditions [1].  As a 53 
result, replacing chemical processes by biological ones for the synthesis of chiral 54 
compounds has been extensively investigated not only due to superior stereo-selectivity 55 
of enzymatic reactions but also due to sustainability as an implementation of green 56 
chemistry [2-5]. One example is the production of hydroxyacids, a family of versatile 57 
chiral molecules containing one hydroxyl group and one carboxyl group [6]. These 58 
molecules have the potential to serve as useful chiral building blocks for a diverse range 59 
of products, including polyhydroxyalkanoates (PHAs) (biodegradable polymers) and 60 
optically-active fine chemicals, such as pharmaceuticals, vitamins, antibiotics, and flavor 61 
compounds [7-10]. Naturally, hydroxyacids are primarily found to be polymerized as 62 
PHAs where they serve as intracellular storage materials for numerous microbes. Those 63 
PHAs consist mostly of monomers with 3-hydroxy, 4-hydroxy, and 5-hydroxy groups 64 
with different lengths of main and side chains [11].  65 
Among the hydroxyacid monomers, 3-hydroxybutyrate (3HB) is the most prolific, 66 
with several reports on engineering E. coli for its production from renewable feedstocks 67 
[5, 12-15]. Biosynthesis of 3HB begins with the condensation of two acetyl-CoA 68 
molecules, a commonly found cellular metabolite regardless of carbon source (Fig. 1). 69 
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However, economically-feasible production of longer-chain hydroxyacids is complicated 70 
by issues such as low yields and high prices of feedstocks due to the need to supplement 71 
a second carbon source. One example of such hydroxyacids is 3-hydroxyvalerate (3HV).  72 
The production of 3HV has been realized by the hydroxylation of valeric acid through 73 
fermentation of Candida rugosa [16]. It has also been reported that 3-74 
hydroxyvaleronitrile can be converted into 3HV using the nitrilase activity of 75 
Comamonas testosteroni [17]. More recently, direct biological production of 3HV was 76 
demonstrated using recombinant P. putida KT2440 and levulinic acid as substrate, 77 
although the levulinic acid metabolism pathway in P. putida KT2440 has not yet been 78 
fully elucidated [18]. In the aforementioned cases, valeric acid, 3-hydroxyvaleronitrile, 79 
and levulinic acid were supplied as secondary carbon sources (in addition to glucose).  80 
Additionally, the chirality and/or enantiopurity of the 3HV produced in the above-81 
mentioned studies is unclear as they did not report whether the synthesized 3HV was in 82 
the R, S, or racemic form. Alternatively, 3HV can be obtained through either the in vivo 83 
or in vitro enzymatic depolymerization of synthesized poly(3-hydroxybutyrate-co-3-84 
hydroxyvalerate) (PHBV), a well known biodegradable polymer marketed as Biopol™ 85 
which is produced by the natural PHA accumulating bacterium Ralstonia eutropha when 86 
grown on glucose and propionate [19]. The production of PHBV has also been reported 87 
in recombinant E. coli upon introduction of the PHA biosynthesis genes of R. eutropha 88 
and when grown in glucose medium supplemented with valine or threonine [20]. 89 
Regardless of whether the end product is 3HV or PHBV, it can be generally concluded 90 
that supplementation of a second carbon source, such as valeric acid, 3-91 
hydroxyvaleronitrile, levulinic acid, propionate, valine, or threonine in addition to 92 
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glucose, is necessary to provide the 5-carbon unit precursor of 3HV. Unfortunately, the 93 
high price and/or toxicity of the added second carbon sources could limit industrial 94 
production of 3HV [21]. Therefore, synthesis of 3HV from a single carbon source has 95 
been proposed as an efficient and sustainable avenue in contrast to the above-mentioned 96 
systems.  97 
A novel pathway for the production of PHBV solely from glycerol has been 98 
established in recombinant Salmonella enterica Serovar Typhimurium, containing a 99 
heterologous pathway that converts succinyl-CoA to propionyl-CoA, the essential 100 
precursor molecule of 3HV-CoA in PHBV synthesis [22]. However, expensive 101 
cyanocobalamin (CN-B12) was supplemented to the medium to provide the precursor of 102 
coenzyme B12 required for the activity of one of the enzymes in the B12-dependent 103 
biosynthetic pathway. It should also be noted that the pathway only functioned in S. 104 
enterica, a pathogen, but not E. coli, thus limiting its applicability to other industrially-105 
relevant host organisms. In this study, we proposed an alternative biosynthetic pathway 106 
that does not require coenzyme B12 for its functionality to synthesize 3HV from glucose 107 
or glycerol. Specifically, we metabolically engineered E. coli to exploit its native 108 
metabolism for endogenous supply of propionyl-CoA via the threonine biosynthesis 109 
pathway, and introduced a heterologous pathway for chiral 3HV biosynthesis using 110 
acetyl-CoA and propionyl-CoA as precursor molecules. As stated above, several previous 111 
methods for producing 3HV did not focus on enantiopure synthesis.  Similarly, due to the 112 
stereospecific constraints of PHBV synthesis, in which polymers are composed 113 
exclusively of (R)-3HB and (R)-3HV monomer units, the synthesis of (S)-3HV from 114 
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PHBV remains effectively impossible. On the contrary, our proposed pathway makes 115 
possible the direct synthesis of both enantiomerically pure (R)-3HV and (S)-3HV.  116 
We have identified a pathway which combines elements of our previously 117 
developed chiral 3HB biosynthesis pathway together with the natural threonine 118 
biosynthesis pathway of E. coli for direct biosynthesis of chiral 3HV (Fig. 1). In the 119 
proposed pathway, chiral 3HV is produced from direct hydrolysis of 3HV-CoA catalyzed 120 
by a thioesterase II (encoded by tesB) where 3HV-CoA is obtained from condensation of 121 
one acetyl-CoA and one propionyl-CoA to form 3-ketovaleryl-CoA catalyzed by a 122 
thiolase (encoded by bktB), followed by a reduction of the 3-ketovaleryl-CoA to 3HV-123 
CoA catalyzed by a 3-hydroxybutyryl-CoA dehydrogenase. Here, two enantio-selective 124 
3-hydroxybutyryl-CoA dehydrogenases were utilized to control the chirality of 3HV-125 
CoA produced. The NADPH-dependent dehydrogenase encoded by phaB produces (R)-126 
3HV-CoA while the NADH-dependent dehydrogenase encoded by hbd produces (S)-127 
3HV-CoA. It should be noted that in order to yield the highest 3HV titers and 3HV/3HB 128 
ratios, BktB was used as the thiolase in this study as opposed to other thiolases such as 129 
PhaA from R. eutropha H16 or Thil from C. acetobutylicum ATCC 824 because BktB 130 
has been shown to have highest in vitro enzyme activity towards the C5 substrate while 131 
PhaA and Thil were specific towards the C4 substrate [19].  Next, a pathway allowing for 132 
endogenous propionyl-CoA synthesis from glucose or glycerol, through the threonine 133 
metabolic pathway intermediate 2-ketobutyrate, was introduced to circumvent the need 134 
for feeding propionate.  To examine the upstream pathway for endogenous supply of 135 
propionyl-CoA, we used a bottom-up approach where 2-ketobutyrate and threonine were, 136 
at first, fed to provide propionyl-CoA, in addition to glucose, to support 3HV production. 137 
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In the final stage, a single carbon source of glucose or glycerol was used to provide both 138 
acetyl-CoA and propionyl-CoA to support 3HV biosynthesis in our metabolically 139 
engineered E. coli. 140 
Overall, in this study we successfully demonstrated the direct biological 141 
production of enantiomerically pure (R)-3HV and (S)-3HV from a single carbon source. 142 
Improvements of the biosynthetic pathway and E. coli host strains have also been carried 143 
out to elevate 3HV titers and 3HV/3HB ratios. 144 
145 
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Results 146 
3HV Synthesis from Glucose and propionate  147 
Acetyl-CoA is an obligate central intermediate occurring in any organism and 148 
under any physiological condition; however, this is not the case for propionyl-CoA, 149 
which is only synthesized under special physiological conditions and from only few 150 
substrates [23]. Therefore, synthesis of 3HV-CoA requires propionyl-CoA biosynthesis. 151 
To validate our 3HV biosynthesis pathway, propionate was initially fed to provide 152 
propionyl-CoA as a precursor molecule to ensure the downstream pathway was capable 153 
of making chiral 3HV.  It has been reported that the R. eutropha PHA biosynthesis genes 154 
can be functionally expressed in E. coli, resulting in homopolymer PHB production from 155 
glucose [24]. However, low levels of 3HV monomer within the synthesized co-polymer 156 
PHBV was observed in recombinant E. coli when propionate was co-fed with glucose in 157 
a way analogous to the procedure used for R. eutropha [24]. One explanation for the low 158 
content of 3HV monomer is that E. coli does not possess an efficient system for 159 
importing and/or converting propionate to propionyl-CoA. Therefore, to address the 160 
propionate utilization problem, a CoA-activation mechanism (encoded by the ptb-buk 161 
operon [25]) was incorporated into our previously developed 3HB pathway to investigate 162 
the substrate elasticity of the pathway for 3HV production.  163 
Our results show that, in the absence of the CoA-activation mechanism, i.e. Ptb-164 
Buk, only trace amount of 3HV was produced (Fig. 2). On the contrary, introducing Ptb-165 
Buk into the pathway yielded up to 2 g/L of both enantiomers of 3HV. It was noted that 166 
for strains expressing Ptb-Buk but leaving out TesB, only (R)-hydroxyacids (when PhaB 167 
was employed) were produced, consistent with a previous report that Ptb-Buk forms a 168 
  
 10 
reversible, stereo-seletive enzyme system [13]. Overall, these results indicate that CoA-169 
activation was crucial for propionate utilization and, most importantly, all enzymes 170 
originally utilized for 3HB biosynthesis were able to catalyze synthesis of C5 molecules. 171 
 172 
3HV Synthesis from Glucose and 2-Ketobutyrate 173 
Propionyl-CoA can also be produced from 2-ketobutyrate, a common keto-acid 174 
intermediate for isoleucine biosynthesis, by the action of the endogenous pyruvate 175 
dehydrogenase complex enzyme (encoded by PDHc) (Fig. 1) [26].  We first compared 176 
3HV production from glucose and 2-ketobutyrate using pathways with and without over-177 
expression of the ptb-buk operon.  The results showed that the presence of Ptb-Buk 178 
reduced production of propionate (only observed in the R-isomer construct) and 3HB 179 
while increasing production of acetate and 3HV, yielding (S)-3HV and (R)-3HV with 180 
titers up to 0.38 g/L and 1.02 g/L, respectively (Fig. 3). The increased production of 181 
acetate and 3HV was presumably due to the promiscuous activity of Ptb-Buk on cleaving 182 
excess acetyl-CoA and activating excess propionate. Given that 3HB production is a 183 
second-order reaction should have a rate proportional to the square of the concentration 184 
of acetyl-CoA, a reduced acetyl-CoA pool resulting from the promiscuous activity of Ptb-185 
Buk likely caused a significant decrease in 3HB production. In addition, propionyl-CoA 186 
is a competing substrate for BktB, so an increase in propionyl-CoA concentration may 187 
also reduce 3HB production. 188 
In an effort to decrease acetate and increase 3HV production, several genes, 189 
including atoDA (encoding acetoacetyl-CoA transferase), poxB (encoding pyruvate 190 
oxidase), and ackA-pta (encoding acetate kinase and phosphate acetyltransferase) were 191 
deleted, and the resulting strain was designated as HCT 20. The production of (S)-3HV 192 
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and (R)-3HV was further boosted to titers of 0.60 g/L and 2.04 g/L, respectively, in the 193 
recombinant acetate pathway knockout strains (HCT 20). In general, those strains 194 
produced less acetate and propionate and yielded more 3HB and 3HV compared to 195 
strains without these mutations (based on HCT 10), probably due to preserved acetyl-196 
CoA and propionyl-CoA pools as a result of the introduced mutations. An empty-plasmid 197 
control experiment has also been conducted in the strain HCT 20 (that was not introduced 198 
with the 3HV pathway), yielding only trace amounts of acetate and propionate when 199 
grown in LB supplemented with glucose and 2-ketobutyrate (data not shown). This 200 
indicates that the production of acetate and propionate in the recombinant HCT 20 was 201 
attributed to the introduced CoA-cleaving activity conferred by ptb-buk and tesB.  202 
 203 
3HV Synthesis from Glucose and Threonine  204 
The metabolic intermediate 2-ketobutyrate can be produced from threonine by the 205 
action of threonine deaminase.  Co-feeding of threonine with glucose, together with over-206 
expression of E. coli threonine deaminase (encoded by ilvA), was able to achieve 207 
production of (S)-3HV and (R)-3HV with titers up to 0.11 g/L and 0.22 g/L, respectively 208 
(Fig. 4). Given that E. coli threonine deaminase is subject to feedback inhibition by 209 
isoleucine, a feedback resistant gene from Corynebacterium glutamicum [27] was also 210 
used, and the production of (S)-3HV and (R)-3HV was further boosted to titers of 0.27 211 
g/L and 0.91 g/L, respectively, under the same culture conditions. This experiment has 212 
also been conducted in the recombinant acetate pathway knockout strains (HCT 20); 213 
however, no improvement in production of 3HB and 3HV was observed (data not 214 
shown).  215 
 216 
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3HV Synthesis from Glucose 217 
We have demonstrated the production of chiral 3HV from glucose supplemented 218 
with propionate, 2-ketobutyrate, or threonine, in recombinant E. coli. The next step is to 219 
construct a threonine over-producing strain in an attempt to achieve 3HV biosynthesis 220 
from a single carbon source. To do so, we up-regulated the threonine biosynthesis 221 
pathway by over-expressing the thrABC opeon, cloned from the wild type E. coli or the 222 
threonine producer E. coli ATCC 21277 that has a single amino acid alteration in the 223 
homoserine dehydrogenase (encoded by thrA
G1297A
) for relieved feedback-inhibition [28]. 224 
Transcriptional attenuation of those genes was removed by replacing the native promoter 225 
with a T7lac promoter, allowing for IPTG-inducible expression. In addition, the 226 
pathways that compete with threonine formation as well as degrade threonine were 227 
eliminated by knocking out metA (encoding homoserine O-succinyltransferase) and tdh 228 
(encoding threonine dehydrogenase) genes, yielding strain HCT 21.  229 
Our results showed that there was essentially no difference in 3HV production 230 
between strains expressing the wild type and feedback resistant thrA (data not shown) 231 
probably because threonine did not accumulate or its level was not high enough to exert a 232 
feedback inhibition to ThrA. We also compared 3HV production across three different E. 233 
coli strains, including HCT 10, HCT 20, and HCT 21. The mutants HCT 20 and HCT 21 234 
carrying only empty plasmids significantly reduced acetate production to 0.22 g/L as 235 
opposed to 1.85 g/L by HCT 10 (Fig. 5); however, recombinant mutant HCT 20 or HCT 236 
21 containing the 3HV pathway produced as much acetate as the recombinant HCT 10, a 237 
counterintuitive finding (see Discussion). The deletions of metA and tdh enhanced (S)-238 
3HV production by 41% (recombinant HCT 21 relative to recombinant HCT 20), but 239 
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essentially had no effect on (R)-3HV production. Nevertheless, those mutations were able 240 
to boost the ratios of 3HV/3HB by decreasing the 3HB titers and/or increase the 3HV 241 
titers. Overall, titers as high as 0.31 g/L and 0.50 g/L of (S)-3HV and (R)-3HV were 242 
achieved in the recombinant HCT 21 with 3HV/3HB ratios up to 0.35 and 0.24, 243 
respectively (Fig. 5).   244 
 245 
3HV Synthesis from Glycerol 246 
Glycerol has become a promising and abundant carbon source due to its 247 
generation as an inevitable byproduct of biodiesel production from vegetable oils or 248 
animal fats through a transesterification reaction [29]. There have been several reports on 249 
converting glycerol to more valuable compounds such as thymidine, ethanol, and 1,3-250 
propanediol [30-32]. Glycerol is also more reduced than glucose, leading to a higher 251 
reduced cofactor pool in the cytoplasm [32]. Therefore, in addition to glucose, we 252 
investigated the ability of our recombinant E. coli to convert glycerol to chiral 3HV. 253 
Titers of 0.08 g/L and 0.96 g/L of (S)-3HV and (R)-3HV, respectively, were achieved in 254 
recombinant HCT 10, while recombinant HCT 21 produced 0.19 g/L and 0.60 g/L of (S)-255 
3HV and (R)-3HV, respectively (Fig. 6). As mentioned in the Materials and Methods 256 
section, in this specific experiment, concentration of 3HB was quantified by DAD at 210 257 
nm that had a detection limit at around 0.08 g/L. As a result, the amounts of (S)-3HB 258 
produced in both recombinant HCT 10 and HCT 21 strains were too low to be quantified 259 
so that we could not report the 3HV/3HB ratios. Nonetheless, in the case of (R)-isomers, 260 
3HV/3HB ratios could be as high as 0.88 and 1.10, respectively, in recombinant HCT 10 261 
and HCT 21 strains. The high 3HV/3HB ratios can be beneficial in terms of product 262 
separation or biosynthesis of PHBV that enables high 3HV content. 263 
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  264 
Confirmation of 3HV Stereochemistry 265 
The stereochemistry of the resulting 3HV in the media from these cultures was 266 
determined by methyl esterification of the 3HV present followed by chiral HPLC analysis 267 
using our previously developed method [15]. However, we could not assign an absolute 268 
stereochemistry to each sample due to the unavailability of enantiopure 3HV standards. 269 
However, based on our previous results regarding the product stereochemistry of phaB 270 
and hbd and the observation that Me-(R)-3HB has a faster retention time relative to Me-271 
(S)-3HB, we expect Me-(R)-3HV to have a faster retention time than Me-(S)-3HV when 272 
analyzed by the same method. Thus, the 6.9 and 9.2 min peaks likely represent Me-(R)-273 
3HV and Me-(S)-3HV, respectively (Fig. 7). These results confirm the enantiopurity of 274 
biosynthesized 3HV. 275 
 276 
Discussion 277 
In general, two approaches can be taken to engineer E. coli for direct 3HV 278 
production via the threonine biosynthesis pathway. The first is to utilize an existing 279 
threonine producer, such as E. coli ATCC 21277 [33], followed by further engineering to 280 
introduce our constructed 3HV pathway. However, this and other available threonine 281 
producing strains have typically been developed through multiple rounds of random 282 
mutagenesis and selection due to the difficulty of engineering this highly regulated and 283 
complex metabolic network. Although there are several successful cases in developing 284 
industrial threonine producers by such approaches, resultant strains usually also suffer 285 
from undesired phenotypes including, for example, growth retardation, low 286 
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transformation efficiency, and by-product formation as a result of random mutations [34]. 287 
In addition, other uncharacterized mutations may hinder further strain development as 288 
often needed. Fortunately, recent advances in computational genomics have allowed for 289 
rational development of production strains [34]. Therefore, as a second approach, a 290 
genetically-defined threonine producing strain was established and introduced with the 291 
3HV pathway to achieve direct microbial production of chiral 3HV from glucose or 292 
glycerol. 293 
As seen in Fig 5, acetate is the major byproduct to the production of hydroxyacids 294 
(3HB and 3HV). In an effort to decrease acetate and increase 3HV production, a mutant 295 
strain HCT 20 with deletions on atoDA, poxB, and ackA-pta genes was developed. 296 
Counter-intuitively, the recombinant acetate pathway knockout strains of HCT 20 and 297 
HCT 21 produced slightly more acetate and less 3HB than recombinant HCT 10. We 298 
suspected that the enzymatic activity responsible for acetate production was restored by 299 
Ptb-Buk and TesB in the recombinant HCT 20 and HCT 21. In fact, in a separate 300 
experiment, both enzymes were found to have CoA-removing activities on acetyl-CoA 301 
and propionyl-CoA (data not shown), so an introduction of TesB and/or Ptb-Buk to 302 
strains HCT 20 or HCT 21 would likely restore the ability to produce acetate.  303 
Apparently, knocking out enzymes responsible for acetate production failed to 304 
reduce acetate synthesis. Alternatively, to alleviate the substrate promiscuity of TesB and 305 
Ptb-Buk on acetyl-CoA, and thus reduce acetate production, one approach called enzyme 306 
co-localization could be implemented to allow substrate channeling between enzymes 307 
[35]. For example, pathway enzymes of Hbd and TesB, catalyzing successive reactions, 308 
can be co-localized in an attempt to reduce the amount of freely floating TesB that may 309 
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hydrolyze acetyl-CoA as well as to increase accessibility of 3HV-CoA by TesB. The 310 
spatial organization of the enzymes can be achieved using either the leucine zipper, a 311 
dimer resulting from interaction between leucine residues [36], or the synthetic scaffolds, 312 
constructed from protein–protein interaction domains [37]. Furthermore, expressing 313 
enzymes that would assimilate produced acetate is another way to reduce acetate 314 
accumulation. For example, acetyl-CoA synthetase (encoded by acs) from E. coli can be 315 
over-expressed to convert acetate to acetyl-CoA with the use of one ATP. While 316 
successfully demonstrated in one work [38], in our case, over-expression of acs was 317 
found to have essentially no effect on acetate reduction (data not shown). Additionally, to 318 
overcome the hurdle of acetate reduction, approaches like protein engineering of TesB 319 
and/or Ptb-Buk to alleviate their substrate promiscuity, or utilization of better isozymes 320 
with more stringent substrate specificity could also mitigate the carbon loss in the form of 321 
acetate. 322 
Among microbes, NADH and NADPH play a central role in energy metabolism 323 
by providing the cell with the reducing power for a variety of cellular redox reactions. 324 
The availability of such cofactors could impose a huge impact on the functionality of 325 
introduced biosynthetic pathways. In fact, we have previously shown that the 326 
NADPH/NADP
+
 ratio was two- to three-fold higher than the NADH/NAD
+
 ratio under 327 
the culture conditions examined, presumably affecting in vivo activities of PhaB and Hbd 328 
and resulting in greater production of (R)-3HB than (S)-3HB [15]. Given that our 329 
proposed 3HV pathway was based on the previously established 3HB pathway, it was 330 
also expected to see the same trend of greater production of (R)-3HV than (S)-3HV, even 331 
though the cofactor dependency of 3HV synthesis may be complicated by the 332 
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energetically expensive threonine biosynthesis pathway with utilization of both ATP and 333 
NADPH. In an effort to perturb the cofactor balance within the cells, thereby tuning the 334 
production of (R)-3HV and (S)-3HV, we attempted to used glycerol, a promising, 335 
abundant, and highly-reduced carbon source, to support 3HV production. Based on our 336 
calculation of reducing equivalents (e
-
) of glucose and glycerol, on the same basis of 2 337 
moles of phosphoenolpyruvate synthesized, glucose and glycerol possess, respectively, 338 
24 and 28 reducing equivalents. Potentially, the additional four reducing equivalents can 339 
be utilized to generate two NADPH or equivalent amount of ATP. In fact, it has been 340 
experimentally confirmed that a higher intracellular NADPH/NADP
+
 ratio was observed 341 
when glycerol was used as a carbon source than glucose, and this higher ratio was also 342 
reflected in boosted production of thymidine as its biosynthesis requires NADPH as a 343 
cofactor [32]. Given that both NADPH and ATP play a central role in threonine 344 
biosynthesis, we hypothesized that the use of glycerol, which could generate more 345 
NADPH and ATP (Fig. 1) relative to glucose, may favor threonine biosynthesis by 346 
directing more carbon flux towards production of propionyl-CoA, thus favoring the 347 
formation of 3HV relative to 3HB. In agreement with our hypothesis, a higher 3HV/3HB 348 
ratio was obtained in the (R)-3HV production when glycerol was used as the carbon 349 
source (Fig. 6). In addition, much larger ratios of the total (R)-hydroxyacids (summation 350 
of (R)-3HB and (R)-3HV titers) to the total (S)-hydroxyacids (summation of (S)-3HB and 351 
(S)-3HV titers) were observed in glycerol-fed cultures (Fig. 6) compared to glucose-fed 352 
cultures (Fig. 5). We hypothesize that the higher intracellular NADPH/NADP+ ratio as a 353 
result of the use of glycerol would favor (R)-hydroxyacid biosynthesis compared to the 354 
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use of glucose, thus yielding the larger ratios of total (R)-hydroxyacids to total (S)-355 
hydroxyacids.  356 
As mentioned previously, BktB was chosen as the primary thiolase due to its high 357 
enzymatic specificity towards the C5 substrate. Given that E. coli has an endogenous 358 
thiolase (encoded by atoB), a deletion of atoB was expected to increase the ratio of 359 
3HV/3HB as AtoB has been shown to prefer to condense two molecules of acetyl-CoA 360 
instead of one propionyl-CoA and one acetyl-CoA [19]. However, our preliminary result 361 
showed that the recombinant HCT 11 with an atoB deletion behaved exactly as the 362 
recombinant HCT 10, and the deletion in atoB had essentially no effect on 3HV 363 
production (data not shown), implying that atoB may not be a constitutively expressed 364 
gene. In addition, it is noteworthy that increased 3HV production in the recombinant 365 
HCT 20 relative to the recombinant HCT 10 was observed only with 2-ketobutyrate 366 
supplementation (Fig. 3) but not with the threonine supplementation, solely glucose, or 367 
solely glycerol experiments (Fig. 4-6); similarly, an accumulation of propionate only 368 
occurred in the 2-ketobutyrate supplementation experiment (Fig. 3), altogether, indicating 369 
that 3HV biosynthesis from glucose or glycerol is most likely limited by the precursor 370 
propionyl-CoA. Therefore, approaches to increase the availability of propionyl-CoA 371 
could enhance the 3HV production.  372 
 373 
Conclusions 374 
Carbon skeletons with even-chain number are naturally found in fatty acid 375 
metabolism, but those with odd-chain number are pretty novel. As a result, there is a 376 
good deal of interest in making odd-carbon chain molecules such as 3HV (C5) and 377 
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propionate (C3) because they are so much harder to get to than even-carbon chain ones 378 
such as acetate (C2) and butyrate/butanol (C4). This paper opens the way for biosynthesis 379 
of the odd-carbon chain molecules from renewable feedstocks. Taking together, our work 380 
represents the first report of direct microbial production of enantiomerically pure 3HV 381 
from a single carbon source. In addition, we have explored the production of each 382 
stereoisomer of 3HV across different genetically altered E. coli strains, along with 383 
various enzyme homologs, for enhanced chiral 3HV production. Further engineering of 384 
host strains and pathway enzymes should lead to higher 3HV titers and a more 385 
economical bioprocess for the production of chiral 3HV. 386 
 387 
Methods 388 
Microorganisms 389 
The bacterial strains used are listed in Table 1. C. acetobutylicum ATCC 824, C. 390 
glutamicum ATCC 13032, and a threonine hyper-producer E. coli ATCC 21277 were 391 
purchased from the American Type Culture Collection (ATCC, Manassas, VA).  R. 392 
eutropha H16 was provided by Professor Anthony Sinskey of the Department of Biology 393 
at the Massachusetts Institute of Technology (Cambridge, MA, USA).  E. coli DH10B 394 
(Invitrogen, Carlsbad, CA) and ElectroTen-Blue (Stratagene, La Jolla, CA) were used for 395 
transformation of cloning reactions and propagation of all plasmids.  MG1655 (kindly 396 
donated by Professor Gregory Stephanopoulos of the Department of Chemical 397 
Engineering at the Massachusetts Institute of Technology, USA) was used as the parental 398 
strain for genetic modification. Host gene deletions of endA, recA, atoDA, ackA-pta, 399 
poxB, tdh, metA, and atoB were achieved with P1 transduction using the Keio collection 400 
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strains as donor cells [39]. The kanamycin cassette was removed using plasmid pCP20 as 401 
described by Datsenko and Wanner [40] and the successfully constructed mutant strains 402 
were verified by colony PCR using appropriate primers. Strains carrying a λDE3 lysogen 403 
were constructed using a λDE3 Lysogenization Kit (Novagen, Darmstadt, Germany) for 404 
site-specific integration of λDE3 prophage into each host. 405 
 406 
Plasmid Construction 407 
Genes derived from C. acetobutylicum ATCC 824 (hbd and ptb-buk operon), R. 408 
eutropha H16 (bktB and phaB), C. glutamicum ATCC 13032 (ilvA), E. coli MG1655 409 
(tesB, ilvA, and thrABC opeon), and E. coli ATCC 21277 (thrA
G1297A
BC opeon) were 410 
obtained by polymerase chain reaction (PCR) using genomic DNA (gDNA) templates.  411 
All gDNAs were prepared using the Wizard Genomic DNA Purification Kit (Promega, 412 
Madison, WI).  Custom oligonucleotides (primers) were purchased for all PCR 413 
amplifications (Sigma-Genosys, St. Louis, MO) as listed in Table 1.  In all cases, Phusion 414 
High Fidelity DNA polymerase (Finnzymes, Espoo, Finland) was used for DNA 415 
amplification. Restriction enzymes and T4 DNA ligase were purchased from New 416 
England Biolabs (Ipswich, MA).  Recombinant DNA techniques were performed 417 
according to standard procedures [41]. Three co-replicable vectors, pETDuet-1, 418 
pCDFDuet-1, and pCOLADuet-1 (Novagen, Darmstadt, Germany), were used for 419 
construction of chiral 3HV biosynthetic pathways [42].  All vectors contain two multiple 420 
cloning sites (MCS), each of which is preceded by a T7lac promoter and a ribosome 421 
binding site (RBS), affording high-level expression of each individual gene.  422 
Plasmids constructed in the present work are listed in Table 1.  For cloning genes, 423 
PCR products incorporated with desired restriction sites within the 5' and 3' primers were 424 
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digested, and the resulting DNA fragments were then cloned into pETDuet-1, 425 
pCDFDuet-1, or pCOLADuet-1.  The bktB gene was inserted in between the MfeI and 426 
XhoI sites (MCS II) of pETDuet-1 to create pET-B. The ptb-buk gene, digested from 427 
pCDF-PB with EcoRI and NotI [15], was inserted between the EcoRI and NotI sites 428 
(MCS I) of pET-B to create pET-PB-B. Plasmid pCDF-H was created by inserting the 429 
hbd gene between the NdeI and AvrII sites (MCS II) of pCDFDuet-1. Cloning the tesB 430 
gene between the NcoI and NotI sites (MCS I) of pCDFDuet-1 resulted in plasmid pCDF-431 
T. Plasmid pCDF-T-H was then created by inserting the hbd gene between the NdeI and 432 
AvrII sites (MCS II) of pCDF-T. In a similar manner, plasmid pCDF-P was created by 433 
inserting the phaB gene between the MfeI and AvrII sites (MCS II) of pCDFDuet-1. 434 
Plasmid pCDF-T-P was created by inserting the phaB gene between the MfeI and AvrII 435 
sites (MCS II) of pCDF-T. Plasmids of pCOLA-Iec and pCOLA-Icg were constructed by 436 
inserting the E. coli ilvA and C. glutamicum ilvA, respectively, between the NdeI and 437 
AvrII sites (MCS II) of pCOLADuet-1. The thrABC operon from MG1655 was inserted 438 
in between the NcoI and SalI sites (MCS I) of pCOLADuet-1 to create pCOLA-Tec. 439 
Plasmid pCOLA-Tec-Icg was then created by inserting the C. glutamicum ilvA gene 440 
between the NdeI and AvrII sites (MCS II) of pCOLA-Tec. To construct plasmid 441 
pCOLA-Tecm-Icg, the thrA
G1997A
BC operon from E. coli ATCC 21277 was inserted in 442 
between the BamHI and SalI sites (MCS I) of pCOLA-Icg. All constructs were confirmed 443 
to be correct by restriction enzyme digestion and nucleotide sequencing.   444 
 445 
Culture Conditions  446 
Seed cultures of the recombinant strains were grown in LB medium at 30°C 447 
overnight on a rotary shaker at 250 rpm.  For the biosynthesis of chiral 3HV, the seed 448 
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cultures were used to inoculate 50 mL LB medium supplemented with 20 g/L glucose or 449 
20 g/L glycerol at an inoculation volume of 2% in 250 mL flasks. Cultures were then 450 
incubated at 30°C on a rotary shaker until OD600 reached 0.8~1.0. At this point, 1 mM 451 
IPTG was added to the cultures to induce recombinant protein expression. Following 452 
induction, cells were cultivated at 30°C and sampled at 24 h intervals for up to 72 h post-453 
induction for HPLC analysis. We found that both 3HB and 3HV titers did not reach a 454 
plateau until 48 h and that there was essentially no difference in the titers between 48 h 455 
and 72 h. Accordingly, only the peak titers observed at 48 h were reported in this study. 456 
In some experiments as indicated, 20 mM (~1.92 g/L) sodium propionate, 3 g/L sodium 457 
2-ketobutyrate, or 3 g/L threonine was added into the cultures at the same time of 458 
induction. In all cases, LB medium was supplemented with 50 mg/L ampicillin, 50 mg/L 459 
streptomycin, and 30 mg/L kanamycin, as appropriate. In general, experiments were 460 
performed in triplicates, and data are presented as the averages and standard deviations of 461 
the results. 462 
 463 
Metabolite Analysis 464 
Samples were centrifuged to pellet cells while the aqueous supernatant was 465 
collected for HPLC analysis. Products of interest, including 3HB, 3HV, glucose, 466 
glycerol, 2-ketobutyrate, acetate, and propionate, were analyzed via HPLC using an 467 
Agilent 1100 series instrument equipped with a refractive index detector (RID) and a 468 
diode array detector (DAD). Given that the 3HB peak is overlapped with the glycerol 469 
peak in the RID chromatogram, detection of 3HB in the glycerol-fed cultures was 470 
achieved using the DAD at 210 nm. Analyte separation was achieved using an Aminex® 471 
HPX-87H anion exchange column (Bio-Rad Laboratories, Hercules, CA) with 5 mM 472 
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H2SO4 as the mobile phase. The mobile phase was pumped at a constant rate of 0.6 473 
mL/min, and the column and detector temperatures were each set at 35°C throughout. 474 
Concentrations were determined by linear extrapolation from calibration of external 475 
standards. 476 
 477 
Chiral Analysis of 3HV 478 
The stereochemistry of 3HV produced was determined by methyl esterification of 479 
the 3HV present in the medium followed by chiral HPLC analysis as described in a 480 
previously reported method [15]. The chiral analysis was performed on an Agilent 1100 481 
Series instrument equipped with a Chiralcel OD-H column (0.46 cm φ x 25 cm) 482 
purchased from Daicel Chemical Industries (West Chester, PA).  Methyl-3HV was 483 
detected on a DAD at 210 nm. The mobile phase was 9:1 n-hexane:isopropanol and the 484 
flow rate through the column was 0.7 mL/min.  Due to unavailability of standards of 485 
Methyl-(R)-3HV and Methyl-(S)-3HV, these spectra were compared to a racemic 3HV 486 
standard (Epsilon Chimie, Brest, France) derivatized by methyl esterification. 487 
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Figures 633 
Figure 1  - Schematic representation of chiral 3HV production via the threonine 634 
biosynthesis pathway in metabolically engineered E. coli  635 
Genes in bold are overexpressed while disrupted pathway steps are indicted by the “no” 636 
symbols. The carbon sources and main metabolic products in the system are enclosed by 637 
rectangular boxes with thick and thin lines, respectively. For glycerol utilization [43, 44], 638 
a glycerol kinase (GK) phosphorylates glycerol to glycerol-3-phosphate, followed by 639 
oxidation to dihydroxyacetone phosphate that enters glycolysis. The oxidation reaction is 640 
catalyzed by a membrane enzyme called glycerol-3-phosphate dehydrogenase (GlpD) 641 
with concomitant production of ubiquinol (UQH2) from ubiquinone (UQ). Electrons 642 
stored in the ubiquinol are then transferred through the aerobic respiratory chain coupled 643 
with proton translocation from cytoplasm to periplasm. Both ATP and NADPH can be 644 
synthesized by an H
+
-driven proton movement from periplasm to cytoplasm, catalyzed by 645 
an ATP synthase and a membrane-bound transhydrogenase (PntAB), respectively.  646 
 647 
Figure 2  - 3HV biosynthesis from glucose and propionate 648 
This figure shows shake-flask production of chiral 3HV by recombinant E. coli strain 649 
HCT 10 grown in LB supplemented with 20 g/L glucose and 20 mM sodium propionate. 650 
Over-expressed genes are indicated in the table below the graph. 651 
 652 
Figure 3  - 3HV biosynthesis from glucose and 2-ketobutyrate 653 
This figure shows shake-flask production of chiral 3HV by recombinant E. coli grown in 654 
LB supplemented with 20 g/L glucose and 3 g/L sodium 2-ketobutyrate. Effects of 655 
overexpressing ptb-buk and using acetate pathway knockout strain HCT 20 (with 656 
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additional deletions of ackA-pta. poxB, and atoDA genes compared to HCT 10) on 3HV 657 
production are compared. All strains contained the same set of plasmids pET-PB-B, and 658 
pCDF-T-H (for (S)-3HV synthesis) or pCDF-T-P (for (R)-3HV synthesis). 659 
 660 
Figure 4  - 3HV biosynthesis from glucose and threonine 661 
This figure shows shake-flask production of chiral 3HV by recombinant E. coli strain 662 
HCT 10 grown in LB supplemented with 20 g/L glucose and 3g/L threonine. Chiral 3HV 663 
production using alternative threonine deaminases (encoded by ilvA) from E. coli and C. 664 
glutamicum is compared. All strains contained the same set of plasmids pET-PB-B, 665 
pCOLA-Icg or pCOLA-Iec as indicated, and pCDF-T-H (for (S)-3HV synthesis) or 666 
pCDF-T-P (for (R)-3HV synthesis).  667 
 668 
Figure 5  - 3HV biosynthesis solely from glucose 669 
This figure shows shake-flask production of chiral 3HV in various knock-out strains as 670 
described in Table 1. Cells were grown in LB supplemented with 20 g/L glucose. The top 671 
and bottom dashed lines represent the acetate titers produced from E. coli strain HCT 10 672 
and HCT 20 harboring empty plasmids, respectively. All strains contained the same set of 673 
plasmids pET-PB-B, pCOLA-Tecm-Icg, and pCDF-T-H (for (S)-3HV synthesis) or 674 
pCDF-T-P (for (R)-3HV synthesis).  The recombinant HCT 10 strains carrying an empty 675 
pCOLAduet-1 in place of pCOLA-Tecm-Icg, as control strains, produced essentially no 676 
3HV (data not shown). 677 
 678 
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Figure 6  - 3HV biosynthesis solely from glycerol 679 
This figure shows shake-flask production of chiral 3HV in various knock-out strains as 680 
described in Table 1. Cells were grown in LB supplemented with 20 g/L glycerol. The 681 
amounts of (S)-3HB produced in both recombinant HCT 10 and HCT 21 strains were too 682 
low to be quantified due to a low detection limit by DAD at 210 nm; therefore, the 683 
3HV/3HB ratios were not applicable (NA) to the (S)-isomer. All strains contained the 684 
same set of plasmids pET-PB-B, pCOLA-Tecm-Icg, and pCDF-T-H (for (S)-3HV 685 
synthesis) or pCDF-T-P (for (R)-3HV synthesis).  686 
 687 
Figure 7 - Determination of the stereochemistry of 3HV  688 
HPLC spectra of (A) racemic 3HV standards after boiling in methanol, (B) culture 689 
medium from the recombinant strain HCT 10 expressing bktB, phaB, tesB, and ptb-buk 690 
after boiling in methanol, and (C) culture medium from the recombinant strain HCT 10 691 
expressing bktB, hbd, tesB, and ptb-buk after boiling in methanol are shown. 692 
 693 
694 
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Tables 695 
Table 1  - E. coli strains, plasmids and oligonucleotides used 696 
Name Relevant Genotype Reference 
Strains   
DH10B F
-
 mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 
endA1 araD139Δ(ara, leu)7697 galU galK λ- rpsL nupG  
Invitrogen 
ElectroTen-Blue Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac Kan
r
 [F´ proAB lacI
q
ZΔM15 Tn10 
(Tet
r
)] 
Stratagene 
MG1655 F
-
 λ- ilvG- rfb-50 rph-1 ATCC 700926 
HCT 10 MG1655 ∆endA ∆recA (DE3) This study 
HCT 11 MG1655 ∆endA ∆recA ∆atoB (DE3) This study 
HCT 20 MG1655 ∆endA ∆ackA-pta ∆atoDA ∆poxB (DE3) This study 
HCT 21 MG1655 ∆endA ∆ackA-pta ∆atoDA ∆poxB ∆metA ∆tdh (DE3) This study 
Plasmids 
  
pETDuet-1 ColE1(pBR322) ori, lacI, T7lac, Amp
R
 Novagen 
pCDFDuet-1 CloDF13 ori, lacI, T7lac, StrepR Novagen 
pCOLADuet-1 COLA ori, lacI, T7lac, KanR Novagen 
pET-B pETDuet-1 harboring bktB from R. eutropha H16 This study 
pET-PB-B a pETDuet-1 harboring ptb-buk operon from C. acetobutylicum 
ATCC 824, and bktB from R. eutropha H16 
This study 
pCDF-H pCDFDuet-1 harboring hbd from C. acetobutylicum ATCC 824 This study 
pCDF-T-H a pCDFDuet-1 harboring tesB from E. coli MG1655, and hbd from 
C. acetobutylicum ATCC 824 
This study 
pCDF-P pCDFDuet-1 harboring phaB from R. eutropha H16 This study 
pCDF-T-P a pCDFDuet-1 harboring tesB from E. coli MG1655, and phaB 
from R. eutropha H16 
This study 
pCOLA-Iec pCOLADuet-1 harboring ilvA from E. coli MG1655 This study 
pCOLA-Icg pCOLADuet-1 harboring ilvA from C. glutamicum This study 
pCOLA-Tec-Icg a pCOLADuet-1 harboring thrABC operon from E. coli MG1655, 
and ilvA from C. glutamicum ATCC 13032 
This study 
pCOLA-Tecm-Icg a pCOLADuet-1 harboring thrA
G1297A
BC operon from E. coli 
ATCC 21277, and ilvA from C. glutamicum ATCC 13032 
This study 
Primers
b
 Sequence 5'→3'c 
 
bktB_US_EcoRI GAATTCATGACGCGTGAAGTGGTAGTG Sigma-Genosys 
bktB_DS_XhoI CTCGAGCGCAAGGCTAACCTCAGAT Sigma-Genosys 
hbd_US_NdeI  ATTCATATGAAAAAGGTATGTGTTATAGG Sigma-Genosys 
hbd_DS_AvrII ATTCCTAGGCAGGTCGACTCTAGAACTTA Sigma-Genosys 
phaB_US_MfeI ATTCAATTGACGAAGCCAATCAAGGAG Sigma-Genosys 
phaB_DS_AvrII ATTCCTAGGGGTCAGCCCATATGCAG Sigma-Genosys 
tesB_US_NcoI ATTCCATGGGCATGAGTCAGGCGCTAA Sigma-Genosys 
tesB_DS_NotI ATTGCGGCCGCGACTCTAGAGACTTAATTGTG Sigma-Genosys 
ilvAec_US_NdeI ATTACATATGGCTGACTCGCAAC Sigma-Genosys 
ilvAec_DS_AvrII ATTACCTAGGCATTTTTCCCTAACC Sigma-Genosys 
ilvAcg_US_NdeI ATTACATATGAGTGAAACATACGTGTC Sigma-Genosys 
ilvAcg_DS_AvrII ATTACCTAGGCCTTCAGCTATGTTTA Sigma-Genosys 
thrABC_US_BamHI ATTAGGATCCAAGGAGATATATCATGCGAGTGTTGAAG Sigma-Genosys 
  
 34 
thrABC_US_NcoI ATTACCATGGGCATGCGAGTGTTGAAG Sigma-Genosys 
thrABC_DS_SalI ATTAGTCGACGATAATGAATAGATTTTACTGATG Sigma-Genosys 
 
a 
Each gene is under the control of the T7lac promoter with a ribosome binding site. 
b 
Primers were synthesized at Sigma-Genosys, St. Louis, MO. 
c 
Restriction enzyme sites used in the cloning are shown in underlined italics. 
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